{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T01:07:45Z","timestamp":1773104865024,"version":"3.50.1"},"publisher-location":"Berlin, Heidelberg","reference-count":27,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642373275","type":"print"},{"value":"9783642373282","type":"electronic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013]]},"DOI":"10.1007\/8904_2013_214","type":"book-chapter","created":{"date-parts":[[2013,2,20]],"date-time":"2013-02-20T02:37:32Z","timestamp":1361327852000},"page":"1-6","source":"Crossref","is-referenced-by-count":7,"title":["Enzyme Replacement Therapy in a Patient with Gaucher Disease Type III: A Paradigmatic Case Showing Severe Adverse Reactions Started a Long Time After the Beginning of Treatment"],"prefix":"10.1007","author":[{"given":"Filippo","family":"Vairo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Netto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Dorneles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzana","family":"Mittelstadt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matheus","family":"Wilke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divair","family":"Doneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristiane","family":"Michelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila Blos","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Quevedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiane","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiele","family":"Nalin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f4nia","family":"Lueska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida Vanessa D.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,2,21]]},"reference":[{"key":"214_CR02141","unstructured":"Brazilian Ministry of Health Guidelines for Gaucher disease In Editor ed.^eds. Book Brazilian Ministry of Health Guidelines for Gaucher disease.\n                \n                  http:\/\/portal.saude.gov.br\/portal\/arquivos\/pdf\/pcdt_doenca_de_gaucher_pdf"},{"issue":"1","key":"214_CR02142","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/glycob\/cwp138","volume":"20","author":"B Brumshtein","year":"2010","unstructured":"Brumshtein B, Salinas P, Peterson B et al (2010) Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages. Glycobiology 20(1):24\u201332","journal-title":"Glycobiology"},{"issue":"9214","key":"214_CR02143","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","volume":"355","author":"T Cox","year":"2000","unstructured":"Cox T, Lachmann R, Hollak C et al (2000) Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355(9214):1481\u20131485","journal-title":"Lancet"},{"issue":"2","key":"214_CR02144","first-page":"275","volume":"47","author":"N Dahl","year":"1990","unstructured":"Dahl N, Lagerstrom M, Erikson A, Pettersson U (1990) Gaucher disease type III (Norrbottnian type) is caused by a single mutation in exon 10 of the glucocerebrosidase gene. Am J Hum Genet 47(2):275\u2013278","journal-title":"Am J Hum Genet"},{"issue":"6","key":"214_CR02145","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s10545-007-0577-z","volume":"30","author":"EH Davies","year":"2007","unstructured":"Davies EH, Erikson A, Collin-Histed T, Mengel E, Tylki-Szymanska A, Vellodi A (2007) Outcome of type III Gaucher disease on enzyme replacement therapy: review of 55 cases. J Inherit Metab Dis 30(6):935\u2013942","journal-title":"J Inherit Metab Dis"},{"key":"214_CR02146","first-page":"3635","volume-title":"Metabolic and molecular bases of inherited disease, Vol II","author":"E Beutler","year":"2001","unstructured":"Beutler E, Grabowski GA (2001) Gaucher disease. In: Scriver CR, Sly WS, Childs B, Beaudet AL, Valle D, Kinzler KW, Vogelstein B (eds) Metabolic and molecular bases of inherited disease, Vol II. McGraw Hill, New York, pp 3635\u20133668"},{"issue":"6","key":"214_CR02147","doi-asserted-by":"publisher","first-page":"854","DOI":"10.2174\/138920111795542624","volume":"12","author":"D Elstein","year":"2011","unstructured":"Elstein D (2011) Recent advances in treatment approaches to Gaucher disease. Curr Pharm Biotechnol 12(6):854\u2013860","journal-title":"Curr Pharm Biotechnol"},{"issue":"1","key":"214_CR02148","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bcmd.2011.09.009","volume":"48","author":"D Elstein","year":"2012","unstructured":"Elstein D, Altarescu G, Maayan H et al (2012) Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from Jerusalem. Blood Cells Mol Dis 48(1):45\u201350","journal-title":"Blood Cells Mol Dis"},{"issue":"7","key":"214_CR02149","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1182\/blood-2007-02-075960","volume":"110","author":"D Elstein","year":"2007","unstructured":"Elstein D, Dweck A, Attias D et al (2007) Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood 110(7):2296\u20132301","journal-title":"Blood"},{"issue":"16","key":"214_CR021410","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1517\/14656560903270520","volume":"10","author":"CE Hollak","year":"2009","unstructured":"Hollak CE, de Fost M, van Dussen L, Vom Dahl S, Aerts JM (2009) Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose - response relationships. Expert Opin Pharmacother 10(16):2641\u20132652","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"214_CR021411","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.bcmd.2009.09.006","volume":"44","author":"CE Hollak","year":"2010","unstructured":"Hollak CE, vom Dah S, Aerts JM et al (2010) Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol Dis 44(1):41\u201347","journal-title":"Blood Cells Mol Dis"},{"issue":"3","key":"214_CR021412","doi-asserted-by":"publisher","first-page":"e714","DOI":"10.1542\/peds.2007-0665","volume":"121","author":"KH Kim","year":"2008","unstructured":"Kim KH, Decker C, Burton BK (2008) Successful management of difficult infusion-associated reactions in a young patient with mucopolysaccharidosis type VI receiving recombinant human arylsulfatase B (galsulfase [Naglazyme]). Pediatrics 121(3):e714\u2013717","journal-title":"Pediatrics"},{"issue":"20","key":"214_CR021413","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1182\/blood-2010-06-293902","volume":"116","author":"E Lukina","year":"2010","unstructured":"Lukina E, Watman N, Arreguin EA et al (2010) Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood 116(20):4095\u20134098","journal-title":"Blood"},{"issue":"3","key":"214_CR021414","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281(3):249\u2013254","journal-title":"JAMA"},{"issue":"1","key":"214_CR021415","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ajh.21888","volume":"86","author":"PK Mistry","year":"2011","unstructured":"Mistry PK, Cappellini MD, Lukina E et al (2011) A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Am J Hematol 86(1):110\u2013115","journal-title":"Am J Hematol"},{"issue":"8","key":"214_CR021416","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ajh.20908","volume":"82","author":"PK Mistry","year":"2007","unstructured":"Mistry PK, Sadan S, Yang R, Yee J, Yang M (2007) Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. Am J Hematol 82(8):697\u2013701","journal-title":"Am J Hematol"},{"issue":"2","key":"214_CR021417","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.clinthera.2011.12.017","volume":"34","author":"JL Morris","year":"2012","unstructured":"Morris JL (2012) Velaglucerase alfa for the management of type 1 Gaucher disease. Clin Ther 34(2):259\u2013271","journal-title":"Clin Ther"},{"issue":"8","key":"214_CR021418","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.clinthera.2005.08.004","volume":"27","author":"GM Pastores","year":"2005","unstructured":"Pastores GM, Barnett NL, Kolodny EH (2005) An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. Clin Ther 27(8):1215\u20131227","journal-title":"Clin Ther"},{"issue":"6","key":"214_CR021419","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jpeds.2009.05.033","volume":"155","author":"DG Peroni","year":"2009","unstructured":"Peroni DG, Pescollderungg L, Piacentini GL, Cassar W, Boner AL (2009) Effective desensitization to imiglucerase in a patient with type I Gaucher disease. J Pediatr 155(6):940\u2013941","journal-title":"J Pediatr"},{"issue":"5311","key":"214_CR021420","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1126\/science.276.5311.428","volume":"276","author":"FM Platt","year":"1997","unstructured":"Platt FM, Neises GR, Reinkensmeier G et al (1997) Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science 276(5311):428\u2013431","journal-title":"Science"},{"issue":"1\u20132","key":"214_CR021421","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ymgme.2004.08.015","volume":"83","author":"E Sidransky","year":"2004","unstructured":"Sidransky E (2004) Gaucher disease: complexity in a \u201csimple\u201d disorder. Mol Genet Metab 83(1\u20132):6\u201315","journal-title":"Mol Genet Metab"},{"key":"214_CR021422","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1749-6632.2011.06387.x","volume":"1250","author":"KJ Sowerwine","year":"2012","unstructured":"Sowerwine KJ, Holland SM, Freeman AF (2012) Hyper-IgE syndrome update. Ann N Y Acad Sci 1250:25\u201332","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"214_CR021423","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ymgme.2006.09.003","volume":"90","author":"K Starzyk","year":"2007","unstructured":"Starzyk K, Richards S, Yee J, Smith SE, Kingma W (2007) The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol Genetics Metabol 90(2):157\u2013163","journal-title":"Mol Genetics Metabol"},{"issue":"2","key":"214_CR021424","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1023\/A:1005495229655","volume":"22","author":"A Tylki-Szymanska","year":"1999","unstructured":"Tylki-Szymanska A, Czartoryska B (1999) Enzyme replacement therapy in type III Gaucher disease. J Inherit Metab Dis 22(2):203\u2013204","journal-title":"J Inherit Metab Dis"},{"issue":"12","key":"214_CR021425","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3324\/haematol.2011.059071","volume":"97","author":"L Dussen","year":"2012","unstructured":"van Dussen L, Cox TM, Hendriks EJ et al (2012) Effects of switching from a reduced dose imiglucerase to velaglucerase in type 1 Gaucher disease: clinical and biochemical outcomes. Haematologica 97(12):1850\u20131854","journal-title":"Haematologica"},{"issue":"5","key":"214_CR021426","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s10545-009-1164-2","volume":"32","author":"A Vellodi","year":"2009","unstructured":"Vellodi A, Tylki-Szymanska A, Davies EH et al (2009) Management of neuronopathic Gaucher disease: revised recommendations. J Inherit Metab Dis 32(5):660\u2013664","journal-title":"J Inherit Metab Dis"},{"issue":"22","key":"214_CR021427","doi-asserted-by":"publisher","first-page":"5767","DOI":"10.1182\/blood-2011-07-366955","volume":"118","author":"A Zimran","year":"2011","unstructured":"Zimran A, Brill-Almon E, Chertkoff R et al (2011) Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 118(22):5767\u20135773","journal-title":"Blood"}],"container-title":["JIMD Reports","JIMD Reports - Volume 11"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/8904_2013_214","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T05:18:22Z","timestamp":1557551902000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/8904_2013_214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"ISBN":["9783642373275","9783642373282"],"references-count":27,"URL":"https:\/\/doi.org\/10.1007\/8904_2013_214","relation":{},"ISSN":["2192-8304","2192-8312"],"issn-type":[{"value":"2192-8304","type":"print"},{"value":"2192-8312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}